Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(19)30935-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Maintenance therapy for chronic lymphocytic leukaemia.
Cochrane Database Syst Rev
January 2024
Division of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Background: Chronic lymphocytic leukaemia (CLL) is the most common lymphoproliferative disease in adults and currently remains incurable. As the progression-free period shortens after each successive treatment, strategies such as maintenance therapy are needed to improve the degree and duration of response to previous therapies. Monoclonal antibodies, immunomodulatory agents, and targeted therapies are among the available options for maintenance therapy.
View Article and Find Full Text PDFAlemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity.
Brain
June 2022
Department of Neurology with Institute of Translational Neurology, University Hospital Muenster, 48149 Muenster, Germany.
Alemtuzumab is a monoclonal antibody that causes rapid depletion of CD52-expressing immune cells. It has proven to be highly efficacious in active relapsing-remitting multiple sclerosis; however, the high risk of secondary autoimmune disorders has greatly complicated its use. Thus, deeper insight into the pathophysiology of secondary autoimmunity and potential biomarkers is urgently needed.
View Article and Find Full Text PDFCase Report: "Primary Immunodeficiency"-Severe Autoimmune Enteropathy in a Pediatric Heart Transplant Recipient Treated With Abatacept and Alemtuzumab.
Front Immunol
April 2022
Department of Pediatrics, Division of Rheumatology/Immunology, Washington University in St. Louis, St. Louis, MO, United States.
Disorders of immune dysregulation following heart transplantation in children have been reported; however, the management of such disorders remains uncertain and challenging. In this case report, we describe a clinical course of a child with severe autoimmune enteropathy after a heart transplant in infancy and detail a treatment approach with abatacept and alemtuzumab. A 21-month-old girl with a medical history of congenital dilated cardiomyopathy and heart transplantation at 2 months was evaluated for chronic hematochezia.
View Article and Find Full Text PDFLow vitamin D levels do not predict risk of autoimmune disease following alemtuzumab treatment for multiple sclerosis.
Mult Scler Relat Disord
March 2022
Menzies Health Institute Queensland, Gold Coast Campus, Griffith University QLD 4222, Australia; Department of Neurology, Gold Coast University Hospital, Southport QLD 4215, Australia.
Article Synopsis
- * A study examined the relationship between vitamin D levels and the development of autoimmune diseases post-treatment, analyzing complete data from 113 patients with a median follow-up of 4.4 years.
- * The findings indicated that lower vitamin D levels do not correlate with increased autoimmunity risk; instead, being female and having a higher EDSS score at treatment were associated with greater risk.
Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis.
BMJ Open
November 2021
School of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia
Introduction: Disease-modifying therapies (DMTs) are the mainstay of treatment for relapsing-remitting multiple sclerosis (RRMS). There is established evidence that DMTs are effective at reducing relapse rate and disease progression in RRMS, but there has been less consideration to the synthesis of MRI and neurocognitive outcomes, which play an increasingly important role in treatment decisions. The aim of this systematic review and network meta-analysis is to examine the relative efficacy, acceptability and tolerability of DMTs for RRMS, using MRI and neurocognitive outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!